Trend Signal Now: The Hot Corner: Director Simeon George Reports a $51 Million $CRSP Buy

Friday, July 18, 2025

Every day, we sift through the filings to spot where the real conviction lies – cutting through the noise to highlight the most meaningful insider moves.

Here's what stood out today:

📌 CRISPR Therapeutics $CRSP – Director Simeon George just dropped a monster $51 million via a Form 4.

That's one of the largest biotech insider buys we've seen all year and a major vote of confidence in gene-editing as a long-term theme.

Here's The Hot Corner, with data from July 17, 2025:

Click the table to enlarge it.

📌 Angiodynamics $ANGO – Point72 just disclosed a fresh 5.20% stake in $ANGO via an original 13G filing.

When a major player like Point72 moves in with a significant passive stake, it's worth paying attention.

Join Hot Corner Insider today and get actionable trade ideas, weekly live video and a monthly special report. Click here!

The Hot Corner Insider

Here's what's happening with The Hot Corner Insider:

We get together on Wednesdays for the Hot Corner Insider Weekly Strategy Session. And we compile the recordings from each and every one in the Strategy Session Archive.

Note that all actionable setups we discuss in The Hot Corner Insider are compiled on the Trade Ideas page.

And please reach out if you have any questions.

Alfonso Depablos | Senior Analyst, All Star Charts

Stock Market Media emails are a financial publication of general circulation and only offers impersonal advice, not tailored to individual needs of a specific client or group. Any comments or statements made herein do not necessarily reflect those of Stock Market Media LLC or its affiliates (collectively, "Stock Market Media") and do not constitute buy or sell recommendations. Unless specifically indicated, this message is not an official confirmation of any transaction. The contents of any email communications to or from Stock Market Media may be monitored or reviewed at Stock Market Media's discretion. Stock Market Media accepts no responsibility for any loss or damage arising in any way from the use of this transmission and any attachments; it is the responsibility of the recipient to ensure that they are virus free. If you reply to this email, please note that we are a public investor and do not want any material non-public information. We do not agree to keep confidential any information you provide and do not agree to any restrictions on our trading activity, except pursuant to a written confidentiality agreement executed by Stock Market Media.

Want to change how you receive these emails? You can manage your preferences here

unsubscribe